Fundz

Verastem Oncology Partners with Oberland Capital and IQVIA for Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian

Jan 13, 2025

Contract Type

partnership

NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Description

Verastem Oncology has announced a strategic commercialization partnership with IQVIA Inc. (IQVIA) to support the potential launch in recurrent KRAS mutant low-grade serous ovarian cancer. The partnership includes a new credit facility for up to $150 million and an equity investment of $7.5 million with Oberland Capital Management LLC.

Company Information

Company

Verastem Oncology

Location

117 Kendrick Street, Suite 500

Needham, Massachusetts, United States

About

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.

Related People

Dan
Likely contact at this company
••••••••@••••••••

See Dan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Verastem Oncology's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Verastem Oncology signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.